Piper Sandler Maintains Overweight on Cardiff Oncology, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has maintained an Overweight rating on Cardiff Oncology (NASDAQ:CRDF) and increased the price target from $5 to $7.
March 01, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Cardiff Oncology and raised the price target from $5 to $7.
The increase in price target by a reputable analyst firm like Piper Sandler typically signals a strong confidence in the company's future performance. This can lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100